Sun Pharma launches innovative psoriasis drug Ilumya in India

Sun Pharmaceutical Industries Limited announced on December 1, 2025, the launch of its innovative drug, Ilumya (Tildrakizumab), in India. This biologic treatment is approved for moderate-to-severe plaque psoriasis and has been widely endorsed by dermatologists globally for its efficacy and safety. India marks the 36th country where Ilumya is now available, with the company noting its consistent demonstration of significant and long-lasting skin clearance.

A clinical study by Sun Pharma in India involving 115 patients with moderate-to-severe plaque psoriasis showed promising results. Skin clearance of 75% or greater was observed in 62.3%, 83.3%, and 93.9% of patients at Weeks 12, 16, and 28, respectively. Furthermore, 90% or greater skin clearance was achieved by 26.3%, 50%, and 78.1% of patients at Weeks 12, 16, and 28. The treatment was well tolerated by Indian patients, with no observed immunogenicity concerns.

Ilumya is a humanized IgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23, inhibiting its interaction with the IL-23 receptor. This leads to the inhibition of pro-inflammatory cytokines and chemokines, making it a sustainable long-term treatment choice for patients.